Successful Treatment of Pediatric Refractory/Relapsed AML with KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy with or without the GO Regimen
| العنوان: | Successful Treatment of Pediatric Refractory/Relapsed AML with KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy with or without the GO Regimen |
|---|---|
| المؤلفون: | Keiichi Isoyama, Kosuke Akiyama, Naoko Okamoto, Ryota Kaneko, Sachio Fujita, Masaya Koganesawa, Yumiko Sugishita, Daisuke Toyama, Ryosuke Matsuno, Shohei Yamamoto |
| المصدر: | Case Reports in Hematology, Vol 2020 (2020) Case Reports in Hematology |
| بيانات النشر: | Hindawi Limited, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, medicine.medical_specialty, Gemtuzumab ozogamicin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, Calicheamicin, medicine, Idarubicin, Case Series, Diseases of the blood and blood-forming organs, business.industry, General Medicine, Fludarabine, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Cord blood, Monoclonal, Cytarabine, FLAG (chemotherapy), RC633-647.5, business, medicine.drug |
| الوصف: | Prognosis in pediatric patients with refractory/relapsed acute myeloid leukemia (AML) is grim, and there is no standard treatment for such patients. Combined treatment with intensive chemotherapy and gemtuzumab ozogamicin (GO), a monoclonal anti-CD33 antibody conjugated with calicheamicin, is useful as reinduction therapy in refractory/relapsed AML. Here, we describe three cases of pediatric refractory/relapsed AML that were successfully managed with FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), with or without GO, as reinduction therapy before a KIR-ligand-mismatched cord blood transplant. This strategy relies on the fact that killer cell immunoglobulin-like receptors (KIR) on cord blood natural killer (NK) cells recognize human leukocyte antigen (HLA) class I alleles, and that donor KIR-ligand incompatibility may be associated with lower incidence of relapse and improved survival in AML, as cells that lack these inhibitory HLA ligands can activate NK cells. All three patients are currently alive and have been disease-free for 24–65 months, although one patient developed severe sinusoidal obstructive syndrome (SOS). Thus, our strategy can result in excellent outcomes in pediatric patients with refractory/relapsed AML. |
| اللغة: | English |
| تدمد: | 2090-6579 2090-6560 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9739c483792be5d3b0e8471280bbb6afTest https://doaj.org/article/c556bb9ce40243518efca8636ccfa444Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9739c483792be5d3b0e8471280bbb6af |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20906579 20906560 |
|---|